SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 21, 1999

BECTON, DICKINSON AND COMPANY				
(Exact name of registrant as specified in its charter)				
New Jersey	001-4802	22-0760120		
(State or other juris- diction of incorporation)		(IRS Employer Iden- tification Number)		
1 Becton Drive, Franklin Lak	, 1	07417-1880		
(Address of principal executive offices)		(Zip Code)		
Registrant's telephone number, including area code		(201) 847-6800		
	N/A			

- ----- (Former name or former addresses if changed since last report.)

Item 5. OTHER EVENTS

On April 21, 1999, the Registrant announced in a press release its results for the second quarter ended March 31, 1999. Attached hereto as Exhibit 99, which is incorporated herein by reference, is a copy of such press release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY (Registrant)

By: /s/ Bridget M. Healy

Bridget M. Healy Vice President and Secretary

Date: April 21, 1999

- 2 -

INDEX TO EXHIBITS

Exhibit Number

Description of Exhibits

99

Press Release issued on April 21, 1999

EXHIBIT 99

R. Jasper - 201-847-7160

April 21, 1999

BECTON DICKINSON REPORTS 18 PERCENT REVENUE INCREASE FOR FISCAL SECOND QUARTER

Franklin Lakes, NJ (April 21, 1999) - Becton Dickinson and Company (NYSE:BDX) announced today results for its fiscal second quarter, which ended March 31, 1999. Diluted earnings per share were \$.34 including a \$.06 per share charge for in-process research and development related to the company's recent acquisition of Biometric Imaging, Inc. Excluding the one-time charge, earnings per share were \$.40, an increase of 14 percent over last year's \$.35.

Reported revenues for the quarter increased by 18 percent from the second quarter of fiscal 1998 to \$874 million. Recent acquisitions contributed to this growth. Excluding the estimated impact of foreign currency translation, revenue growth would have been approximately 17 percent.

By business segment, medical supplies and devices revenues grew 26 percent to \$484 million compared with \$384 million in last year's second quarter. These revenues reflected strong growth from the company's infusion therapy business, which included \$45 million from the April 1998 acquisition of the medical device business (MDD) of the BOC Group. This segment's performance also reflects significant growth in diabetes health care revenues primarily due to unusually low revenues in the prior year's second quarter after a January 1998 price increase.

Diagnostic systems revenues increased to \$390 million, a 10 percent increase over \$355 million in last year's second quarter. Included in these results were strong performances from the flow cytometry, sample collection and tissue culture businesses.

By geographic area, revenues in the United States were \$438 million, a 9 percent increase over the prior year. Revenues outside the United States were \$436 million, a 30 percent increase over last year's \$336 million. The MDD acquisition contributed to the strong revenue growth outside the United States.

Six-Month Results

For the six-month period ended March 31, 1999, revenues were \$1.643 billion, a 14 percent increase over \$1.440 billion a year ago. As previously noted, recent acquisitions contributed to revenue growth. Favorable foreign currency translation added an estimated \$8 million in revenues for the six-month period. Diluted earnings per share were \$.63 including the in-process research and development charge of \$.06. Medical supplies and devices revenues for the six-month period were \$909 million, while revenues from diagnostic systems totaled \$734 million.

Clateo Castellini, chairman, president and chief executive officer, said, "We are pleased that we are seeing the results from our focus on revenue growth, and we expect this to continue in the second half of the year." * * *

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding the company's performance, including future revenues, products and income, or events or developments that the company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of the company and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described in any forward-looking statement. Factors that could cause actual results to vary materially from any

2

forward-looking statement include, but are not limited to, competitive factors, changes in regional, national or foreign economic conditions, changes in interest or foreign currency exchange rates, delays in product introductions, Year 2000 issues, and changes in health care or other governmental regulation, as well as other factors discussed herein and in the company's filings with the Securities and Exchange Commission.

- Selected Financial Schedules Follow -

BECTON DICKINSON AND COMPANY SELECTED FINANCIAL SCHEDULES Amounts in thousands, except per-share data

INCOME STATEMENTS	1999			nded March	
REVENUES	\$873 , 964	4	\$738 , 43	33	18.4
Cost of products sold Selling and administrative Research and development	429,260 233,004 67,251	4	364,08 186,01 43,79	.7	17.9 25.3 53.6
TOTAL OPERATING COSTS AND EXPENSES	729,515	5 	593,89)3	22.8
OPERATING INCOME	144,449	9	144 , 54	0	(0.1)
Interest expense, net Other income (expense), net	(18,758 1,460		3) (11,427) (3,064)		64.2 NM
INCOME BEFORE INCOME TAXES	127 , 151	1	130,04	9	(2.2)
Income tax provision	37,037	7 	37,71	.4	(1.8)
NET INCOME	\$ 90,114	4	\$ 92 , 33	5	(2.4)
EARNINGS PER SHARE					
Basic Diluted	\$ 0.36 \$ 0.34	6 4 	\$ 0.3 \$ 0.3	37 35	(2.7) (2.9)
AVERAGE SHARES OUTSTANDING					
Basic Diluted	249,276 264,814	6 4	244,95 260,67		
NM - Not Meaningful					
SUMMARY OF REVENUES	1999			Inded March	
BY BUSINESS SEGMENT					
Medical Supplies and Devices Diagnostic Systems	390,185	5	354,74	8	10.0
TOTAL REVENUES				3	
BY GEOGRAPHIC AREA					
United States International	435,840	6		1	
TOTAL REVENUES	\$873 , 964	4	\$738 , 43	3	18.4

BECTON DICKINSON AND COMPANY SELECTED FINANCIAL SCHEDULES Amounts in thousands, except per-share data

		Six Months Ended	March 31,
INCOME STATEMENTS	1999	1998	% Change

REVENUES

Cost of products sold Selling and administrative Research and development		456,120		385,157	13.4 18.4 31.8
TOTAL OPERATING COSTS AND EXPENSES	1,	,387,651	1,	192,466	16.4
OPERATING INCOME Interest expense, net Other income (expense), net		255,279 (36,629) 2,485		247,607 (21,668) (5,297)	69.0
INCOME BEFORE INCOME TAXES		221,135		220,642	0.2
Income tax provision		54,863		63,986	(14.3)
NET INCOME	\$	166,272	\$	156,656	6.1
EARNINGS PER SHARE					
Basic Diluted	\$ \$	0.66 0.63	\$ \$	0.63 0.60	4.8 5.0
AVERAGE SHARES OUTSTANDING					
Basic Diluted		248,793 265,314		244,282 259,160	
NM - Not Meaningful					
SUMMARY OF REVENUES		1999			d March 31, % Change
BY BUSINESS SEGMENT					
Medical Supplies and Devices Diagnostic Systems 	\$			756,250 683,823	
TOTAL REVENUES	\$1, 	,642,930	\$1,	440,073	14.1
BY GEOGRAPHIC AREA					
United States International	\$	817,351 825,579		790,747 649,326	3.4 27.1
TOTAL REVENUES	\$1, 	,642 , 930			14.1